Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.
Prostate Cancer Awareness Month: Updates in mCRPC and Radioligand Therapy
Daniel J. George, MD, discusses ongoing research with radioligand therapy in prostate cancer and its potential role in novel settings and combinations.
Sandy Srinivas, MD, discusses the therapeutic landscape of mCRPC and the need to develop novel treatment options.
Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5